Valuation Metrics Signal Changing Market Sentiment
As of 28 July 2026, Makers Laboratories Ltd trades at ₹151.70, up 1.34% from the previous close of ₹149.70. The stock’s 52-week range spans ₹109.00 to ₹186.70, indicating moderate volatility over the past year. However, the key focus for investors remains the company’s valuation metrics, which have undergone a significant recalibration.
The current P/E ratio stands at 38.16, a level that has contributed to the downgrade of the valuation grade from attractive to fair. This multiple is considerably higher than some peers such as Venus Remedies (P/E 18.04) and Syncom Formulations (P/E 16.23), though it remains below the very expensive valuations of Hester Biosciences (P/E 40.38) and Shukra Pharma (P/E 52.23).
Similarly, the price-to-book value ratio of 1.23 suggests a moderate premium over the company’s net asset value, aligning with the fair valuation status. This contrasts with the broader sector where several companies command much higher P/BV multiples, reflecting investor willingness to pay for growth or quality.
Comparative Enterprise Value Multiples
Enterprise value (EV) multiples provide further insight into Makers Laboratories’ valuation stance. The EV to EBITDA ratio is 5.68, which is relatively low compared to peers like Ind-Swift Laboratories (EV/EBITDA 55.82) and NGL Fine Chem (28.28), but also lower than Fredun Pharma’s attractive 17.61. This suggests that while Makers Labs is not overvalued on an EV/EBITDA basis, the market is cautious given its earnings and capital structure.
The EV to EBIT ratio of 8.20 and EV to capital employed of 1.25 reinforce this moderate valuation perspective. These figures indicate that the company’s operating earnings and capital utilisation are priced fairly, but not at a discount that would attract value-focused investors aggressively.
Profitability and Returns: Mixed Signals
Return on capital employed (ROCE) at 15.26% is a positive indicator, signalling efficient use of capital relative to earnings before interest and tax. However, the return on equity (ROE) is notably low at 3.22%, which may raise concerns about shareholder returns and overall profitability. This disparity could be a factor in the cautious stance reflected in the valuation downgrade.
Dividend yield data is not available, which may limit income-focused investor interest. The PEG ratio is recorded as zero, indicating either a lack of meaningful earnings growth projections or data unavailability, further complicating valuation assessments.
Stock Performance Relative to Sensex
Examining Makers Laboratories’ stock returns against the Sensex benchmark reveals a mixed performance. Year-to-date, the stock has surged 28.40%, significantly outperforming the Sensex’s decline of 9.84%. Over one week and one month periods, Makers Labs also posted positive returns of 1.30% and 2.99%, respectively, while the Sensex fell by 1.12% and 0.34%.
Longer-term returns present a more nuanced picture. Over three years, Makers Labs delivered a robust 37.53% gain versus the Sensex’s 15.95%, highlighting strong relative performance. However, over five years, the stock declined by 30.94%, underperforming the Sensex’s 46.13% gain. Over a decade, Makers Labs has appreciated 103.22%, trailing the Sensex’s 174.18% rise.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Sector Peer Comparison Highlights Valuation Risks
Within the Pharmaceuticals & Biotechnology sector, Makers Laboratories’ valuation sits in the middle of a wide spectrum. Companies like Venus Remedies and TTK Healthcare are also rated as fair, with P/E ratios of 18.04 and 21.94 respectively, indicating more conservative valuations. Conversely, firms such as Hester Biosciences, NGL Fine Chem, and Shukra Pharma are classified as very expensive, with P/E multiples exceeding 40 and EV/EBITDA ratios well above 20.
Interestingly, Fredun Pharma is rated attractive despite a P/E of 40.38, likely due to a higher PEG ratio of 0.68, signalling expected earnings growth. Makers Laboratories’ PEG ratio of zero suggests limited growth expectations, which may justify the fair valuation despite a relatively high P/E.
Micro-Cap Status and Market Capitalisation Considerations
Makers Laboratories is categorised as a micro-cap stock, which inherently carries higher volatility and risk compared to larger peers. This status, combined with the recent downgrade from Hold to Sell by MarketsMOJO on 27 July 2026, reflects growing caution among analysts. The Mojo Score of 47.0 and Mojo Grade of Sell underline concerns about the stock’s risk-reward profile in the current market environment.
Investors should weigh these factors carefully, especially given the company’s modest ROE and the absence of dividend yield, which may limit appeal to income or quality-focused portfolios.
Makers Laboratories Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investment Implications and Outlook
The shift in valuation grade from attractive to fair signals a more cautious stance on Makers Laboratories Ltd. While the stock has demonstrated strong short-term and medium-term returns relative to the Sensex, its elevated P/E ratio and modest profitability metrics suggest limited margin for error.
Investors should consider the company’s micro-cap status and the recent downgrade in analyst ratings when evaluating exposure. The fair valuation rating implies that the stock is no longer a clear bargain, especially when compared to peers with more compelling growth prospects or stronger financial metrics.
Given the mixed signals from profitability and valuation multiples, a prudent approach would be to monitor upcoming earnings and sector developments closely. Any improvement in ROE or earnings growth could justify a re-rating, while further deterioration may reinforce the current cautious outlook.
Summary
Makers Laboratories Ltd’s valuation has shifted notably, with the P/E ratio rising to 38.16 and the P/BV at 1.23, prompting a downgrade from attractive to fair. Compared to sector peers, the stock trades at a premium to some and a discount to others, reflecting a nuanced market view. Profitability metrics such as ROCE are reasonable, but low ROE and absent dividend yield temper enthusiasm. The stock’s micro-cap classification and recent downgrade to a Sell rating by MarketsMOJO further highlight risks. Investors should weigh these factors carefully, considering alternative opportunities within the Pharmaceuticals & Biotechnology sector.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
